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Abstract
Background: Exposure to anticancer drugs is hazardous and may lead to chromosomal abnormalities and
spontaneous abortion in healthcare workers. Guidelines recommend surface decontamination and cleaning in
order to minimize the occupational exposure to anticancer drugs, although no single process has been found
to deactivate all currently available hazardous drugs. Ozone gas is oxidative and a decontaminant for bacteria;
its characteristic as a gas has advantages in that it does not need to be wiped off or neutralized after use.
Methods: The nucleoside anticancer drugs, cytarabine and fluorouracil, were exposed to ozone gas on plates
under controlled humidity. The levels of exposed ozone were evaluated using the concentration-time (CT)
value, which is the mathematical product of ozone concentration and exposure time. The effects of exposure
to ozone on levels of the anticancer drugs were determined by high-performance liquid chromatography
(HPLC).
Results: The levels of cytarabine decreased with increasing CT value and were not detected beyond 40,000 CT.
The decomposition levels of the anticancer drug by ozone were CT-dependent irrespective of the maximum
concentration of ozone. Higher humidity in the range from 70 to 90 % accelerated the decomposition of
cytarabine and fluorouracil, and neither of the drugs were detected at 90 % humidity after exposure to
ozone gas.
Conclusions: Ozone gas decomposed these nucleoside anticancer drugs. This is the first report of the
applicability of ozone gas as a decontaminator for anticancer drugs.
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Background
Exposure to anticancer drugs may be hazardous to
healthcare workers, since many of the anticancer drugs
are carcinogenic and teratogenic, and cause reproductive
toxicity, genotoxicity and/or organ toxicity [1]. These
toxicities result in spontaneous abortions and chromo-
somal abnormalities in healthcare workers. Retrospective
studies and meta-analysis revealed an association be-
tween exposure to chemotherapy and spontaneous
abortion [2, 3]. The occurrences of chromosome 5 and 7
abnormalities in peripheral blood of healthcare workers
handling the anticancer drugs were elevated compared to
that in unexposed individuals [4].
In order to minimize the occupational exposure to
anticancer drugs, National Institute of Occupational
Safety and Health (NIOSH) Alert provided recommen-
dations for routine cleaning, decontamination, house-
keeping, and waste disposal [1]. The American Society
of Health System Pharmacists (ASHP) guidelines on
handling hazardous drugs recommended surface decon-
tamination and cleaning using alcohol for disinfection,
which does not deactivate any hazardous drugs and may
result in the spread of contamination [5]. Although no
single process has been found to deactivate all currently
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available hazardous drugs, wiping with sodium hypo-
chlorite solution is recommended as a strong deactivator
of many hazardous drugs followed by wiping with a de-
tergent and thiosulfate neutralizer. However, areas that
are not manually accessible, such as the plenum of a
biological safety cabinet, cannot be cleaned by any wiping
method.
Ozone is a colorless and strongly oxidative gas. It is a
decontaminant for reduction of contamination with
Clostridium difficile and Bacillus subtilis [6, 7]. Because
of its characteristic as a gas, ozone has advantages, such
as ability to reach anywhere, including inaccessible areas
such as a plenum, and there is no need to remove or
neutralize it after use.
This article reports on the applicability of ozone gas as
a potential decontaminator for nucleoside anticancer
drugs to prevent occupational exposure in healthcare
workers. Relative humidity was also found to affect the
oxidative activity of ozone against the named drugs.
Methods
Anticancer drugs
Cyloside N injection from Nippon Shinyaku Co., Ltd. and
5-fluorouracil (5-FU) injection from Kyowa Hakko Kirin
Co., Ltd. were purchased commercially. Twenty mL of
Cyloside N injection contained 40 mg of cytarabine, and
5 mL of 5-FU injection contained 250 mg of fluorouracil
according to the package inserts.
Exposure to ozone gas
Two-hundred micrograms of cytarabine or 500 μg of
fluorouracil, was placed onto stainless-steel plates and
kept at room temperature until dry. Ozone gas was
generated by Handy Clean from Tamura Teco Co., Ltd.
The plates containing the anticancer drugs were placed
in an experimental chamber and exposed to ozone gas.
Humidity in the chamber was determined by humidity
sensor ES2HB (Omron, Kyoto Japan) and increased by
ultrasonic humidifier Bottle Cube (Topland, Shizuoka
Japan). Non-treated control plates were placed in another
experimental chamber without exposure to ozone. The
levels of exposure to ozone were evaluated as CT value
(ppm•min), which is the mathematical product of ozone
concentration (ppm) and exposure time (min). The expo-
sure was performed under the condition in which ozone
concentration and humidity was maintained at 35 ppm
and 90 %, respectvitely and, CT was set at 80,000 unless
otherwise described. After reaching an initially set CT
value, ozone gas was inactivated with activated charcoal
and the amount of anticancer drug remaining was ana-
lyzed by HPLC. All data were shown as mean of tripicte
samples.
HPLC analysis
A Capcell pak C18 MG II from Shiseido Co., Ltd was used
as a column and the detection wavelength was 254 nm.
The mobile phase for cytarabine and fluorouracil was
10 mmol/L phosphate buffer (pH 5.0):acetonitrile (95:5)
and 50 mmol/L phosphate buffer (pH 5.0):methanol
(85:15), respectively. The flow rate was 1 mL/min and the
resulting chromatogram was analyzed using Chromato-
PRO software from Run Time Corporation. The ozone-
exposed and non-exposed control anticancer drugs on the
plates were recovered by wiping the plates with cotton
containing purified water. The reproducibility of HPLC
and recovery rate of anticancer drug from the plate were
examined prior to the ozone exposure experiment and
was satisfactory for further experiments. The non-treated
control levels of the anticancer drugs were estimated
as 100 %.
Results
To evaluate the effect of ozone gas on cytarabine, the
stainless-steel plate was exposed to ozone in a chamber,
in which the humidity was maintained at 90 %. The
levels of cytarabine decreased with an increasing CT
value and were not detected beyond 40,000 ppm•min
(Fig. 1). Next, the effect of the maximum concentration
of ozone on the anticancer drug was examined to reveal
the usefulness of the CT value (Fig. 2). The exposure to
ozone was terminated when the CT value reached
10,000 ppm•min during the experiment, and the max-
imum concentration of ozone was set at 20, 40, and
60 ppm. The levels of cytarabine decreased to approxi-
mately 50 % after exposure to ozone, and no differences
were detected between the groups irrespective of the
maximum concentration of ozone. The effect of the
humidity on the levels of cytarabine during exposure to
ozone is shown in Table 1. The level of cytarabine at





















Fig. 1 Effect of ozone gas on the levels of cytarabine. Data were
mean of tripicte samples
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for the non-treated control group. At 80 % humidity, the
levels of cytarabine decreased to 2.9 % compared with
control and it was undetectable at 90 % humidity. Levels
of fluorouracil after exposure to ozone under various
humidity conditions are shown in Table 2. Ozone had
no effect on the level of fluorouracil at 70 % humidity;
however, the level of fluorouracil at 80 % humidity was
13 % compared to that in control, and was undetectable
at 90 % humidity.
Discussion
Many kinds of approaches, such as the use of closed
systems, are recommended to prevent the occupational
exposure of healthcare workers to anticancer drugs [1, 5].
However, once contamination has occurred, anticancer
drugs spread to the environment and must be cleared
thereafter. Spill kits, which contain solutions of sodium
hydroxide, sodium thiosulfate, detergent, and/or sodium
hypochlorite, are usually recommended for decontami-
nation. Mochizuki et al. [8] showed that paclitaxel and
docetaxel were decomposed by wiping with sodium
hydroxide solution while cyclophosphamide, fluoro-
uracil, and gemcitabine were not. Therefore, no single
process has been found to deactivate all anticancer
drugs to date. In addition, areas that are not access-
ible by hand such as a plenum in a biological safety
cabinet, or areas healthcare workers do not expect to be
contaminated, could not be cleared off using a wiping
method.
Ozone gas is oxidative and has several presumed
advantages when used as a deactivator of the anticancer
drugs. It has a high redox potential and will accomplish
disinfection in addition to decomposing the anticancer
drugs. Ozone, being a gas, can be used to decontaminate
large areas and reach inaccessible locations, and does not
rely on workers identifying surfaces for decontamination.
Since ozone gas can be generated on-site from oxygen in
the air, there are fewer safety and economic problems
associated with shipping and storage. Residual ozone gas
can be also easily decomposed by activated charcoal after
the deactivation of the anticancer drug is complete. On
the other hand, in Occupational Safety & Health Adminis-
tration (OSHA), part of the United States Department of
Labor, guidelines for ozone, ozone levels should never
exceed 0.1 ppm for 8 h per day exposure in the workplace
[9]. The detection limit of ozone gas in human is approxi-
mately 0.01 ppm because of its unique smell, which help
the workers notice and tackle the toxicity of the gas before
they suffer health hazard. However, instruction and careful
handling is needed. Ozone gas is also reactive and corro-
sive, thus requiring the use of a corrosion-resistant mate-
rial such as stainless steel.
It has been shown here that ozone gas decomposes the
nucleoside anticancer drugs cytarabine and fluorouracil.
The decomposition by ozone is CT-dependent and not
dependent on the maximum concentration of ozone. The
decomposition by ozone is also time-dependent if the
concentration of ozone is maintained constant through
the exposure. In addition, higher humidity accelerates
decomposition of the anticancer drugs. Ozone is con-
verted to hydroxyl radicals in the presence of water, which




















Fig. 2 Effect of the maximum concentration of ozone gas on the
levels of cytarabine. Data were mean of tripicte samples
Table 1 Effect of humidity on cytarabine during exposure
of ozone gas
Humidity (%) Ozone exposure Residual cytarabine (%)
Mean SD
70 - 100.9 98.6 100.5 100.0 1.2
+ 88.6 87.5 88.7 88.2 0.7
80 - 100.6 100.3 99.1 100.0 0.8
+ 3.3 2.9 2.5 2.9 0.4
90 - 100.6 98.4 101.0 100.0 1.4
+ 0.0 0.0 0.0 0.0 0.0
Table 2 Effect of humidity on fluorouracil during exposure
of ozone gas
Humidity (%) Ozone exposure Residual fluorouracil (%)
Mean SD
70 - 92.0 102.3 105.7 100.0 7.2
+ 101.7 110.1 111.1 107.6 5.2
80 - 93.8 94.0 112.2 100.0 10.6
+ 0.0 22.1 16.9 13.0 11.6
90 - 96.6 98.3 105.1 100.0 4.5
+ 0.0 0.0 0.0 0.0 0.0
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has higher redox potential and reactivity than ozone [10],
and the elevated levels of humidity might facilitate the
oxidative reactions of the anticancer drugs.
The results reported here suggest that ozone gas can be
a candidate for a decontaminator of anticancer drugs.
Ozone gas has advantages in deactivation of the antican-
cer drugs described above. This is the first report of the
cleanup effects of ozone gas on the nucleoside anticancer
drugs to the best of the authors’ knowledge. Further
research into the applicability of ozone as a decontamina-
tor for anticancer drugs is planned, while further studies
on the activity of ozone with other anticancer drugs are
needed.
Conclusion
It has been demonstrated that ozone gas decomposed
the investigated nucleoside anticancer drugs in a CT-
dependent and humidity-dependent manner. The appli-
cability of ozone gas as a decontaminator for anticancer
drugs can be suggested, since ozone gas has some ad-
vantages in that it can access any site, be generated
on-site from air, and easily deactivated.
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